Experimental drug targets deadly skin cancer in rare blistering disease
Disease control
Completed
This early-phase study tested an experimental drug called rigosertib in just 2 people who have a rare, severe blistering skin disease (recessive dystrophic epidermolysis bullosa) and also developed advanced skin cancer. The goal was to see if the drug could shrink or control the …
Phase: PHASE1, PHASE2 • Sponsor: Prof. Johann Bauer • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC